Relationship between the angiotensin-converting enzyme genotype and the forearm vasodilator response to estrogen replacement therapy in postmenopausal women
Mitsuhiro Sanada, MD, PhD*,
Yukihito Higashi, MD, PhD ,
Keigo Nakagawa, MD,
Shota Sasaki, MD,
Ichiro Kodama, MD*,
Mikio Tsuda, MD*,
Nobutaka Nagai, MD, PhD* and
Koso Ohama, MD, PhD*
* Department of Obstetrics and Gynecology, Faculty of Medicine, Hiroshima University, Hiroshima, Japan
First Department of Internal Medicine, Faculty of Medicine, Hiroshima University, Hiroshima, Japan
View larger version (16K):
[in a new window]
|
Figure 1 Forearm blood flow at rest and during reactive hyperemia in the DD (n = 9), ID (n = 21) and II (n = 25) angiotensin converting enzyne genotype groups at baseline. There was no significant difference in reactive hyperemia between the three groups at baseline.
|
|
View larger version (15K):
[in a new window]
|
Figure 2 Maximal forearm blood flow (FBF) after sublingual administration of nitroglycerin in the DD (n = 9), ID (n = 21) and II (n = 25) ACE genotype groups at baseline and after three months of estrogen replacement therapy (ERT). Changes in FBF similar to those seen before and after ERT were observed in the three groups after the administration of sublingual nitroglycerin. Results are presented as the mean value ± SE. N.S. = not significant.
|
|
View larger version (15K):
[in a new window]
|
Figure 3 Absolute changes in percent maximal forearm blood flow (FBF) during reactive hyperemia after three months of estrogen replacement therapy, according to the ACE genotype. A significant increase in the maximal FBF during reactive hyperemia was seen only in the ID and II genotype groups (*p < 0.05). The results are presented as the mean value ± SE.
|
|
|
